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A long form of tRNase Z (tRNase ZL) can cleave any target RNA at any desired site under the direction
of artiﬁcial small guide RNA including 25-nucleotide hook-shaped RNA. Here we show that human
miR-103 can form a hook structure to guide target RNA cleavage by human cytosolic tRNase ZL in
vitro. In vivo analyses using luciferase mRNAs modiﬁed to contain miR-103 target sequences in their
30 untranslated regions indicated that miR-103 downregulates gene expression through directing
mRNA cleavage by tRNase ZL. The present data suggest the possibility that human cytosolic tRNase
ZL modulates gene expression through a subset of microRNAs in the cells.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Almost 20 years ago, we discovered a four-base-recognizing
RNA cutter termed RNase 65 in mammalian cytosolic extracts,
which is a ribonucleoprotein complex between tRNA 30 processing
endoribonuclease (tRNase Z, or 30 tRNase) and a 30-truncated tRNA
[1–3]. Although its physiological role and genuine substrate RNA
remain to be revealed, RNase 65 recognizes substrate RNA via four
base-pairings with the 50-terminal sequence of the 30-truncated
tRNA (Fig. 1B). tRNase Z is an enzyme that is responsible for
removing a 30 trailer from precursor tRNA (pre-tRNA) (Fig. 1A)
[4,5]. tRNase Zs can be divided into two groups: an 100-kDa long
form (tRNase ZL) and an 40-kDa short form (tRNase ZS) [6].
Although the human genome encodes both, curiously, only tRNase
ZL not tRNase ZS can function as RNase 65 [6,7].
The discovery of RNase 65 encouraged us to study further ver-
satility of mammalian tRNase ZL, and we have demonstratedchemical Societies. Published by E
ndoribonuclease; pre-tRNA,
form of tRNase Z; tRNase ZL,
UE gene silencing, tRNase ZL-
ing RNA; RISC, RNA-induced
o2, Argonaute 2; 30 UTR, 30
himoto).in vitro that tRNase ZL can cleave any target RNA at any desired site
by recognizing a pre-tRNA-like or micro-pre-tRNA-like complex
formed between the target RNA and artiﬁcially-designed small
guide RNA (sgRNA) (Fig. 1) [8–13]. sgRNA is divided into four
groups, 50-half-tRNA, 12–16-nt linear RNA, RNA heptamer, and
hook RNA (Fig. 1C and E–G). Again, tRNase ZS can process pre-
tRNAs but not these pre-tRNA-like or micro-pre-tRNA-like com-
plexes in vitro [6]. We have also demonstrated the efﬁcacy of this
RNA targeting technology in mammalian cells by introducing sgR-
NAs [14–17], and call this method TRUE gene silencing after tRN-
ase ZL-utilizing efﬁcacious gene silencing.
Recently, we have found that there exists 50-half-tRNAGlu
among tRNase ZL-co-immunoprecipitated human noncoding RNAs
(ncRNAs) and that it is predominantly in the cytoplasm [18]. This
observation astonished us since 50-half-tRNA is the very RNA that
we have been using as tailor-made sgRNA for TRUE gene silencing.
We have also shown that the 50-half-tRNAGlu indeed works as
sgRNA in vitro and that human tRNase ZL modulates gene expres-
sion through the 50-half-tRNAGlu [18]. Furthermore, we have dem-
onstrated that the human PPM1F mRNA is one of the genuine
targets of tRNase ZL guided by the 50-half-tRNAGlu.
MicroRNAs (miRNAs) are 21–23-nt RNAs that can play impor-
tant regulatory roles in many processes such as development,
cancer, and apoptosis [19]. An RNA-induced silencing complex
(RISC) charged with a miRNA downregulates gene expression by
repressing its target mRNA translationally or by moving into thelsevier B.V. All rights reserved.
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Fig. 1. Various RNA substrates for human tRNase ZL. (A–C) Pre-tRNA and pre-tRNA-like RNA complexes. (D–G) Micro-pre-tRNA and micro-pre-tRNA-like RNA complexes.
Arrows denote the primary cleavage sites.
3242 R.A. Elbarbary et al. / FEBS Letters 583 (2009) 3241–3246processing body with the mRNA for its degradation [20]. In this
case, miRNA usually has limited complementarity to the target
mRNA with a complete match of residues 2–8 of miRNA called
seed sequence. On the other hand, miRNA that has perfect com-
plementarity can function as small interfering RNA (siRNA), and
guide a target mRNA cleavage by the catalytic component Arg-
onaute 2 (Ago2) in RISC.
Interestingly, a complex of the Caenorhabditis elegans lin-14
mRNA with the lin-4 miRNA has been shown to be recognized
and cleaved by mammalian tRNase ZL in vitro [9]. This suggests a
possibility of intracellular interplay between miRNAs and tRNase
ZL. While, in this case, lin-4 works as a 50-half-tRNA-type sgRNA,
the discovery of a new type of sgRNA, hook RNA, the length of
which is 25 nt similar to that of miRNA [12], inspired us to inves-
tigate whether miRNAs can also function as hook-type sgRNA.
In this paper we show that a subset of human miRNAs can form
hook structures and that hook-type miRNAs can guide target RNA
cleavage by human cytosolic tRNase ZL in vitro. We also present
in vivo data indicating that miRNA downregulates gene expression
through directing mRNA cleavage by tRNase ZL. Taken together, the
present data suggest the possibility that human cytosolic tRNase ZL
modulates gene expression via a subset of miRNAs in the cells.2. Materials and methods
2.1. RNA synthesis
One target RNA and three miRNAs were synthesized with T7
RNA polymerase (Promega) from the corresponding synthetic
DNA templates. The sequences of these RNAs are as follows:
target-1, 50-GAGAAUGCUGCCGGGCUCGCGGAUUU-30; miR-16,
50-GGGCAGCACGUAAAUAUUGGCG-30; miR-98, 50-GGAGGUAGU
AAGUUGUAUUGUU-30; miR-103, 50-GGCAGCAUUGUACAGGGC-U
AUGA-30. The transcription reactions were carried out under the
conditions recommended by the manufacturer (Promega), and
the transcript for the target RNA was labeled with ﬂuorescein
according to the manufacturer’s protocol (GE Healthcare) [18].
miR-103 (50-AGCAGCAUUGUACAGGGCUAUGA-30), antisense of
miR-103 (50-AUAGCCCUGUACAAUGCUGCUGA-30), the four siRNAs
[21] targeting the human Ago2 mRNA, and the 20-O-methyl anti-
miR-103 RNA (50-UCAUAGCCCUGUACAAUGCUGCU-30) were chem-
ically synthesized by Nippon Bioservice. The siRNA targeting the
human tRNase ZL mRNA was obtained from Qiagen: sense, r(GACU
CCGAGUCGAAUGAAA)d(TT); antisense, r(UUUCAUUCGACUCGG
AGUC)d(TG).
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In vitro RNA cleavage assays for the ﬂuorescein-labeled RNA
target-1 were performed as described previously [18].
2.3. Cell culture and transfection
The 293 and HeLa cells were cultured as described previously
[18]. The 293 or HeLa cells were transfected with plasmids or with
plasmids and RNA using Lipofectamine 2000 (Invitrogen). The cells
were usually cultured for further 18 h, and the cells transfected
with the tRNase ZL siRNA or the Ago2 siRNAs were cultured for fur-
ther 42 h.
2.4. Luciferase assay
The modiﬁed luciferase expression plasmids pGL3-T1(103) and
pGL3-T2(103), which produce mlucT1(103) and mlucT2(103),
respectively, were constructed by inserting annealed synthetic
double-stranded DNAs containing the sequences T1(103) (50-TCAT
AGCCCTGTACAATGCTGCT-30) and T2(103) (50-AACAATACAACTT
ACTTGCTGCT-30), respectively, between XbaI and FseI sites of
pGL3-Control vector (Promega). Luciferase assays were performed
as described previously [18].
2.5. Real-time PCR for luciferase mRNA quantitation and 30-RACE
Real-time PCR for luciferase mRNA quantitation and 30-RACE
were performed as described previously [18].
2.6. Statistical analysis
Differences between control and experimental groups were
evaluated by the Student’s t-test.
3. Results and discussion
3.1. Human miR-103 guides target RNA cleavage by tRNase ZL
We found that a subset of human miRNAs including miR-16,
miR-98, and miR-103 can potentially form the hook structure
(Fig. 2A). To see if the hook-type miRNAs can direct RNA cleavage
by tRNase ZL, we examined these three miRNAs for their guiding
ability in vitro. A 26-nt RNA, target-1, which contains a 7-nt se-
quence complementary to the 2nd–8th nt of miR-16 and the 1st–
7th nt of miR-103 but not miR-98 (Fig. 2A), was assayed for cleav-
age by tRNase ZL.
We ﬁrst tested the cytosolic D30 tRNase ZL lacking the N-termi-
nal 30 amino acids [18]. miR-16 and miR-98 did not guide target-1
cleavage by the D30 enzyme, whereas miR-103 efﬁciently directed
the cleavage (Fig. 2B). The inability of miR-16 to guide may be due
to the bulge in the middle of the hairpin stem and/or due to insta-
bility of the hairpin structure. On the other hand, miR-98 efﬁ-
ciently directed tRNase ZL cleavage of the target RNA that
contains a sequence complementary to the 1st–6th nt of miR-98
(data not shown). We also tested nuclear full-length tRNase ZL
for cleavage of the miR-103/target-1 complex [18]. Surprisingly,
the D30 enzyme was much more active than the full-length one
(Fig. 2C), although both enzymes cleaved pre-tRNAArg with the
same efﬁciency [18].
3.2. A part of miRNA molecules exist in a cytosolic free pool
In addition to the cytosolic existence of D30 tRNase ZL [18], the
cytosolic existence of RISC-free miRNA would be required if miRNA
functions as sgRNA, although each mature miRNA molecule is be-lieved to form a complex with RISC [20]. We performed reverse-
transcription PCR analysis for the RNA samples extracted from a
retentate and a ﬁltrate of 293 or HeLa cell extracts separated by
ultraﬁltration with a 30-kDa cut-off membrane, and detected in
both fractions miR-16 and miR-103 from the 293 cells and miR-
16 from the HeLa cells (Supplementary Fig. 1B). We also carried
out western analysis for Ago2 in the retentates and the ﬁltrates,
and detected Ago2 only in both retentates (Supplementary
Fig. 1C), conﬁrming that RISC did not pass through the membrane
during the procedure.
These results suggest that a part of miRNAmolecules indeed ex-
ist in a cytosolic free pool. Furthermore, from real-time PCR analy-
sis, the free miR-103 level was estimated to be at least 1%, which
was much higher than the percentage (0.1%) of the free 5S rRNA
(Supplementary Fig. 1D). Some percentage of the RISC-free miR-
103 molecules could have originated from the experimental proce-
dure per se. On the contrary, the actual percentage of RISC-free
miR-103 could be much higher because a part of RISC-free miR-
103 molecules could be kept binding other cellular, large proteins
and/or RNAs non-speciﬁcally in the retentate during the ultraﬁltra-
tion procedure. Even if only 1% of miR-103 is actually free in the
cells, it may be sufﬁcient to function as sgRNA, considering the dy-
namic behavior of miRNA as discussed below.
3.3. Human tRNase ZL downregulates gene expression via miR-103
Together, the above observations encouraged us to prove the
function of miRNA as sgRNA in the living cells more directly. We
performed ﬁreﬂy luciferase reporter assays using the modiﬁed
pGL3 plasmids that generate luciferase mRNAs, mlucT1(103) and
mlucT2(103), containing in the 30 untranslated region (30 UTR)
the sequences T1(103) and T2(103) complementary to the 1st–
23rd nt and the 1st–7th nt, respectively, of miR-103 (Fig. 3A).
We assumed that free miR-103 works as sgRNA to guide primarily
mlucT2(103) cleavage by tRNase ZL, while RISC-bound miR-103
guides only mlucT1(103) cleavage by RISC. We also assumed that
translational repression of mlucT2(103) by RISC-bound miR-103
would not be strong because only one target sequence exists in
the 30 UTR [22].
In 293 cells, the luciferase expressions from mlucT1(103) and
mlucT2(103), compared with that from the unmodiﬁed luciferase
mRNA mlucT0, were repressed by adding exogenous miR-103 or
siRNA103 made of miR-103 and its antisense, and augmented in
the presence of anti-miR-103 20-O-methyl RNA (Fig. 3B). The ef-
fects of the anti-miR-103 oligonucleotide on the luciferase expres-
sions were relatively small in spite of downregulation of the miR-
103 level by 99.7% (data not shown), suggesting that the endoge-
nous miR-103 level is intrinsically not so high in the 293 cells. Fur-
ther, three pGL3 plasmids were examined for luciferase
expressions in the absence or presence of exogenous miR-103,
which were modiﬁed to generate luciferase mRNAs,
mlucT2(103)M2–mlucT2(103)M4, containing two to four base sub-
stitutions in the sequence T2(103). In contrast to the expression
levels from mlucT2(103), those from mlucT2(103)M2–
mlucT2(103)M4 were not signiﬁcantly affected in the presence of
exogenous miR-103 (Supplementary Fig. 2). Together, these obser-
vations suggest that the luciferase expression from mlucT2(103) is
repressed by miR-103 through its 50 7-nt sequence.
The ratio T2/T1(103) of the expression level frommlucT2(103) to
that from mlucT1(103) was decreased and increased by co-trans-
fecting the tRNase ZL expression plasmid and the tRNase ZL siRNA,
respectively, and also decreased in the presence of the siRNAs to
Ago2 (Fig. 3B). In contrast, as expected from the in vitro RNA cleav-
age assay, there was no signiﬁcant effect of the tRNase ZL level on
the expression level ratio T2/T1(16) of the similarly modiﬁed lucif-
erase mRNAs mlucT1(16) and mlucT2(16) containing miR-16 target
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Fig. 3. Human tRNase ZL downregulates gene expression via miR-103. (A) Schematic of the luciferase assay strategy to distinguish the RISC and tRNase ZL effects. (B)
Luciferase reporter assays with 293 cells. The expression levels from mlucT1(103) and mlucT2(103) are normalized against that from mlucT0 (left). The ratio T2/T1(103) of the
expression level from mlucT2(103) to that from mlucT1(103) is shown in the 293 cells that were co-transfected with the tRNase ZL expression plasmid (+ZL), the tRNase ZS
expression plasmid (+ZS), the tRNase ZL siRNA (ZL), or the Ago2 siRNAs (Ago) (middle and right). Two independent sets of data are presented by blue and red bars, and error
bars indicate S.D. (n = 3). P < 0.01. (C) The ratio of the mlucT2(103) amount to the mlucT1(103) amount in the 293 cells quantitated by real-time PCR. Two independent sets of
data are presented by blue and red bars, and error bars indicate S.D. (n = 3). P < 0.05. (D) Distributions of 30 ends of 50 cleavage products of mlucT1(103) and mlucT2(103). Red
line, expected cleavage site.
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shown).
Consistent with the in vitro observation, the increase in the
tRNase ZS level did not affect the ratio T2/T1(103) signiﬁcantly(Fig. 3B). The same effect of the change in the tRNase ZL level
was also observed at the RNA level on the ratio of the mlucT2(103)
amount to the mlucT1(103) amount (Fig. 3C). In HeLa cells, the ef-
fect of the shift in the tRNase ZL or Ago2 level on T2/T1(103) was
**
Dicer
RISC
cap AAAAA
cap AAAAA
tRNase ZL
miRNA
cap AAAAA
Fig. 4. Mechanisms for generation of miRNA as sgRNA. Several pathways to generate RISC-free miRNA molecules are shown. See text for a detailed description.
R.A. Elbarbary et al. / FEBS Letters 583 (2009) 3241–3246 3245not signiﬁcant (Supplementary Fig. 3), which is consistent with the
observation that the miR-103 level in HeLa cells is only 18% of that
in 293 cells (Supplementary Fig. 1A).
Further we analyzed 30-end sequences of 50 cleavage products
from mlucT1(103) and mlucT2(103) by 30-RACE. The 30 ends of
mlucT1(103) cleavage products were distributed at 3- to 9-nt up-
stream of the expected RISC cleavage site, whereas the distribution
of the 30 ends ofmlucT2(103) cleavage productswas shifted to 13-nt
downstream and was at 3- to 9-nt upstream of the expected tRNase
ZL cleavage site (Fig. 3D). The cleavages at 3- to 9-nt upstream could
be due to 30 to 50 exoribonuclease reactions after the RISC or tRNase
ZL cleavage. All these in vivo observations would be best explained
in the context of the above assumptions, and indicate that miR-103
indeed works as sgRNA for tRNase ZL in the cells.
3.4. A new mechanism for miRNA-mediated silencing
We showed that at least 1% of miR-103 molecules would exist
in a cytosolic pool free from RISC (Supplementary Fig. 1D). There
would be several pathways to generate free miRNA molecules that
can be used as sgRNAs to guide tRNase ZL to target mRNAs (Fig. 4).
After processing of pre-miRNA by Dicer [23], a miRNA antisense
strand would be incorporated into RISC and a miRNA sense strand
would be freed into the cytosol with a certain probability. Even
after the normal processing, the freed antisense strand could be
also used as sgRNA for tRNase ZL. More fundamentally, RISC-bound
miRNA molecules would dissociate from RISC at a certain rate. Fur-
thermore, RISC capturing a mRNA would also dissociate from a
mRNA/miRNA complex with a certain probability, and tRNase ZL
may recognize the complex instead and cleave the mRNA.
Although it is unknown what mRNA targets are cleaved by the
miRNA-guided tRNase ZL, the involvement of tRNase ZL would add
a completely new view to the miRNA-mediated post-transcrip-
tional silencing [19,24–28]. Interestingly, many off-target mRNA
reductions induced by siRNA have been shown to occur via
Ago2-independent degradation processes [29]. And our current re-
sults suggest that some of the off-target effects may be attributable
to tRNase ZL. It should be also noted that the 50 seven or eight nt of
miRNA are important for target recognition in both mechanisms
using tRNase ZL and RISC [30].
Recently, we have also shown that human cytosolic tRNase ZL
modulates gene expression through cellular 50-half-tRNA in the cells
[18]. The present results together with this observation imply that
other types of small cellular ncRNA would also mediate regulation
of gene expression by tRNase ZL. It is now clear that the reason
why the TRUE gene silencing method works well in the cells [14–
17] is because it utilizes artiﬁcial sgRNAs like naturally occurring
ncRNAs and mimics the intrinsic cellular gene regulatory system.Acknowledgements
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